High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006年8月10日 · The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators *
SPARCL - Wiki Journal Club
2017年12月3日 · The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial randomized 4,700 patients with prior stroke or TIA to either high-dose statin …
Atorvastatin in stroke: a review of SPARCL and subgroup analysis
Statin therapy in patients with cardiovascular disease is associated with reduced incidence of stroke. The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial …
SPARCL研究探索性分析：阿托伐他汀更有利于减少卒中后总血管 …
2020年3月18日 · sparcl研究结果显示，在近期发生卒中或tia且无已知冠心病的受试者中，与安慰剂相比，强化阿托伐他汀治疗减少了首次卒中和首次复合血管事件的 ...
SPARCL: the glimmer of statins for stroke risk reduction
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study was designed to be the first prospective clinical trial to consider risk reduction of recurrent stroke as …
Review of the SPARCL trial and its subanalyses - PubMed
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study is a prospective, randomized, placebo-controlled trial that was designed to determine whether 80 …
SPARCL: Atorvastatin Reduces First, Subsequent Vascular Events
2020年3月18日 · In patients with no known coronary heart disease who had a recent stroke or transient ischemic attack, intensive atorvastatin therapy, compared with placebo, reduced the …
SPARCL®分析 - Berthold Technologies GmbH & Co.KG
sparcl®（空间邻近分析物试剂捕获发光）是一种邻近依赖性化学发光技术，用于检测两个结合配偶体之间的特定结合相互作用或缔合。 在SPARCL®分析中，通过化学发光底物（acridan）标 …
Results of the Stroke Prevention by Aggressive Reduction in …
2009年2月19日 · The Stroke Prevention by Aggressive Reduction of Cholesterol Levels (SPARCL) trial randomized 4731 subjects with recent stroke or TIA and no known coronary …
Stroke Prevention by Aggressive Reduction in Cholesterol Levels - SPARCL
2006年9月1日 · The SPARCL trial showed that among patients with prior stroke or TIA, treatment with atorvastatin was associated with a reduction in recurrent stroke compared with placebo. …